Highlights of This Issue  3097

SPECIAL FEATURES

CCR 20th Anniversary Commentary

3099  CCR 20th Anniversary Commentary: Chimeric Antigen Receptors—From Model T to the Tesla
Patrick Hwu

CCR Translations

3102  Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy
Zachary A. Cooper, Alexandre Reuben, Jacob Austin-Breneman, and Jennifer A. Wargo
See related article, p. 3140

3105  Growth Factor Receptor Fusions Predict Therapeutic Sensitivity
Mannert S. Ahluwalia and Jeremy N. Rich
See related article p. 3307

Molecular Pathways

3108  Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy
Diletta Di Mitri, Alberto Toso, and Andrea Alimonti

Reviews

3113  Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy
Atsushi Yonezawa, Suparna Dutt, Cariad Chester, Jeewon Kim, and Holbrook E. Kohrt

3121  Nanotechnology: Future of Oncotherapy
Kshipra M. Gharpure, Sherry Y. Wu, Chun Li, Gabriel Lopez-Berestein, and Anil K. Sood

CANCER THERAPY: CLINICAL

3130  Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning
Muriel Hannon, Yves Béguein, Grégory Ehh, Sophie Servais, Laurence Seidel, Carlos Graux, Johan Maertens, Tessa Kerre, Coline Daulne, Muriel de Bock, Marianne Fillet, Aurélie Orph, Evelyne Willems, André Gothot, Stéphanie Humblet-Baron, and Frédéric Baron

3140  PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients
Hojabr Kakavand, James S. Wilmott, Alexander M. Menzies, Ricardo Vilain, Lauren E. Haydu, Jennifer H. Yearley, John F. Thompson, Richard F. Refford, Peter Hersey, Georgina V. Long, and Richard A. Scoller
See related commentary, p. 3102

3149  Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases
Steven C. Katz, Rachel A. Burga, Elise McCormack, Li Juan Wang, Wesley Moore, Gary R. Point, Pranay D. Khare, Mitchell Thorn, Qianzhong Ma, Brian F. Stainken, Earle O. Assanah, Robin Davies, N. Joseph Espat, and Richard P. Junghans

3150  Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma
Jennifer R. Brown, Matthew S. Davids, Jordi Rodon, Pau Abrisqueta, Siddha N. Kasar, Joanne Lager, Jason Jiang, Coumaran Egile, and Farrukh T. Awan

3170  Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate–Treated Castration-Resistant Prostate Cancer Patients
Xu S. Xu, Charles J. Ryan, Kim Stuyckens, Matthew R. Smith, Fred Saad, Thomas W. Griffin, Youn C. Park, Margaret K. Yu, An Vermeulen, Italo Poggesi, and Partha Nandy

3178  Biologic Activity of Autologous, Granulocyte–Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines
John M. Goldberg, David E. Fisher, George D. Demetri, Donna Neuberg, Stephen A. Allopia, Catin Fonseca, Yuko Nakazaki, David Nemere, Chandrajit P. Raut, Suzanne George, Jeffrey A. Morgan, Andrew J. Wagner, Gordon J. Freeman, Jerome Ritz, Cecilia Lezcano, Martin Mihm, Christine Canning, F. Stephen Hodi, and Glenn Dranoff

PERSONALIZED MEDICINE AND IMAGING

3187  Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children’s Oncology Group
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

Tony Mok, Yi-Long Wu, Jin Soo Lee, Chong-Jen Yu, Vitoir Sutrapong, Jennifer Sandoval-Tan, Guia Ladrera, Sumitra Thongprasert, Vichien Srimuninnimit, Melinl Liao, Yunzhong Zhu, Caicun Zhou, Fatima Fuerte, Benjamin Margono, Wei Wen, Julie Tsai, Matt Truman, Barbara Kluhammer, David S. Shames, and Lin Wu

Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas

Misu Lee, Tobias Wiedemann, Claudia Gross, Ines Leinh€auser, Federico Roncaroli, Rickmer Braren, and Natalia S. Pellegata

Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma


HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL

Robbie Carson, Basak Celikci, Cathy Fenning, Arman Javadi, Nyree Crawford, Lucia Perez-Carbonell, Mark Lawler, Daniel B. Longley, Patrick G. Johnston, and Sandra Van Schaeybroeck

Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate

Preethi Korangath, Wei Wen Teo, Helen Sadik, Liangfeng Han, Noriko Mori, Charlotte M. Huijts, Ronelle Wildes, Santosh Bhujwalla, and Sarawati Sukumar

Head-to-Head Comparison and Evaluation of 92 Plasma Protein Biomarkers for Early Detection of Colorectal Cancer in a True Screening Setting

Hongda Chen, Manuela Zucknick, Simone Werner, Phillip Knebel, and Hermann Brenner

Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma


See related commentary, p. 3105

A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs

Shang-Fan Yu, Bing Zheng, MaryAnn Go, Jeff Lau, Susan Spencer, Helga Raab, Robert Sotiano, Suchit Jhunjhunwala, Robert Cohen, Michele Caruso, Paul Polakis, John Flygare, and Andrew G. Polson

Targeting GLUT1 Expression and GLUT1 Activity in Ovarian Cancer by Using a Peptide Conjugate

Sara de los Rios-Fernandez, Lina E. Lohi, Lucas Simões, Yaroslava M. V. Pershina, Patrick Gehener, and Eliane M. de Souza

See related commentary, p. 3203

A Prevention Trial of a Novel Peptide Antibody (mAb) Conjugate (Acetate) Directed against Apoptosis-Related Glican 3 (AR-G3) Provides Robust Tumor Kicking in a Wide Range of Solid Tumor Malignancies

Yori Asundi, Lisa Crocker, Jarrod Tremayne, Peter Chang, Chie Sakana, Joshua Blumberg, Susan Spencer, Sreevee Chalasani, Elizabeth Luis, Karen Gascoigne, Rupal Desai, Rajiv Raja, Brad A. Friedman, Peter M. Haverty, Paul Polakis, and Ron Firestein

Targeting GLUT1 Expression and GLUT1 Activity in Ovarian Cancer by Using a Peptide Conjugate (Acetate) Directed against Apoptosis-Related Glican 3 (AR-G3) Provides Robust Tumor Kicking in a Wide Range of Solid Tumor Malignancies

Yori Asundi, Lisa Crocker, Jarrod Tremayne, Peter Chang, Chie Sakana, Joshua Blumberg, Susan Spencer, Sreevee Chalasani, Elizabeth Luis, Karen Gascoigne, Rupal Desai, Rajiv Raja, Brad A. Friedman, Peter M. Haverty, Paul Polakis, and Ron Firestein

The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment


XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A


An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies

Jyoti Asundi, Lisa Crocker, Jarrod Tremayne, Peter Chang, Chie Sakanaka, Josh Tanguay, Susan Spencer, Sreedevi Chalasani, Elizabeth Luis, Karen Gascoigne, Rupal Desai, Rajiv Raja, Brad A. Friedman, Peter M. Haverty, Paul Polakis, and Ron Firestein

BIOLOGY OF HUMAN TUMORS
### Table of Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3340</td>
<td>Genetic Modulation of Neurocognitive Function in Glioma Patients</td>
<td>Yanhong Liu, Renke Zhou, Erik P. Sulman, Michael E. Scheurer, Nicholas Boehling, Georgina N. Armstrong, Spiridon Tsavachidis, Fu-Wen Liang, Carol J. Etzel, Charles A. Conrad, Mark R. Gilbert, Terri S. Armstrong, Melissa L. Bondy, and Jeffrey S. Weigel</td>
</tr>
<tr>
<td></td>
<td>CORRECTIONS</td>
<td></td>
</tr>
<tr>
<td>3356</td>
<td>Correction: Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers</td>
<td></td>
</tr>
<tr>
<td>3358</td>
<td>Correction: A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma</td>
<td></td>
</tr>
<tr>
<td>3359</td>
<td>Correction: CTLA4 Blockade Broadens the Peripheral T-cell Receptor Repertoire</td>
<td></td>
</tr>
</tbody>
</table>

**ABOUT THE COVER**

The heatmap shows expression of immune-related genes in endometrial cancers from the TCGA series. POLE proofreading-mutant tumors display evidence of a robust cytotoxic T-cell response. For details, see the article by van Gool and colleagues on page 3347 of this issue.